Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networksA Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications.Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic RadiotherapyTD-11 workshop report: characterization of monoclonal antibodies to S100 proteins.Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental studyB7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcomeMicroRNAs as biomarkers in colorectal cancerClinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer.Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancerNuclear legumain activity in colorectal cancer.Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer.Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.Disseminated tumour cells as a prognostic biomarker in colorectal cancerBiomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial.Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer.MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancerRadiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaPrincipal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report.Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.Clinical significance of disseminated tumour cells in non-small cell lung cancerSystemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.Molecular modelling and simulations in cancer research.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial.Expression and clinical significance of Wee1 in colorectal cancer.Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.Pathway-based classification of breast cancer subtypes.Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer.
P50
Q26991945-C3716928-ACCD-4C22-A7D1-48F9B2033EBDQ30488426-40BDF735-4A19-4525-AA75-84EEE9D19F05Q33289545-CAF84177-FE56-468C-992C-6C9083E5AB7CQ33343721-53A6726E-DC51-413B-9D5B-95D2833E5D5EQ33584050-CB8513F7-1852-4DAF-A68C-626E7EC8FFD4Q33638693-95E59A07-31D2-4697-8EAC-EDCA22CD0C4DQ33681531-87EA6C4D-09F7-4B7E-8C2E-A5A90043926CQ34105913-26B34B28-E159-4D7E-BC10-2C295B50B36DQ34162262-00C6D86B-0061-49DA-A351-3B79119A567FQ34465886-00D0BC1F-3E25-4C65-B5FF-36D0C672EAA6Q34505944-FBB84040-8850-48B9-AF7C-302435FD2EB2Q34551087-78CEEF91-A440-47F1-A619-71E5E3833484Q34793233-BC66B5AC-AD91-409F-B35A-991B70FB6066Q34915905-27B3A9EC-B70A-4C22-AC4B-C8BA46247265Q35005604-1293FC55-96CB-4AE0-967C-63CDDAEBD1EAQ35006944-582493DA-B4FE-4890-9FBE-005E9AB37756Q35108007-5B2B0ABA-C65F-47FD-834E-F4AF434AF4E8Q35175047-C565132E-D9E6-49E8-9C92-CB4A24E6DFF4Q35544528-3FC64346-1532-4DB1-BDA4-85B4F665A630Q35709494-DC96C6BD-92BE-4592-AD4F-87A1042F575FQ35812742-31C38EDB-C438-4FDC-A1A0-F71212F0522CQ36086751-AA05A60E-24B1-49D9-BB87-64FD76B6283AQ36166778-ECCB6FCA-8BCF-452B-B968-D6B27392635EQ36235746-16BFBD70-5B7A-423F-A22E-6594F1C286F3Q36368072-E6F1ED0D-FB8D-4551-A3A7-1FAAC5ED889EQ36649292-18138BA5-9D2A-4CDF-B028-19EC4035C2E0Q36651647-8908CCF1-499B-4EC9-A552-2515C3161CEAQ37148928-BDE38A16-B0F4-4563-B85E-E159E0421197Q37185823-5CC34E5A-73D4-4BE8-AC80-954638706D33Q37376421-629C0028-BCEE-4C9D-A69E-D406BE4ECA79Q37597912-E7C631ED-EEFC-48BD-9B07-4A572CFB6587Q38082249-48F5872A-338D-4945-B9D9-574B7BE3906FQ38263008-D08CF466-B999-4D6D-AFE6-E4A11C73EF44Q38485785-56BF8BD8-507A-416A-B601-2AC1184ABBA4Q38704911-72D0E716-AC07-4443-9C12-47A801340927Q38737092-5715C09D-C09E-4871-809E-D4F767469C3EQ38748006-8FCF3072-56F1-41A9-9D55-0EBD64D4BE9FQ38836784-9DDFE3EA-7CF4-4041-BD2B-60B191C359E2Q38836943-7B5C74E3-B8F7-4EF2-BB30-4BBBE8F891E7Q39099143-B82378EE-EB46-4CFB-8859-C7901E2B0F16
P50
description
Noors onderzoekster
@nl
hulumtuese
@sq
norsk forsker
@nb
researcher
@en
հետազոտող
@hy
name
Kjersti Flatmark
@ast
Kjersti Flatmark
@da
Kjersti Flatmark
@de
Kjersti Flatmark
@en
Kjersti Flatmark
@es
Kjersti Flatmark
@fr
Kjersti Flatmark
@nb
Kjersti Flatmark
@nl
Kjersti Flatmark
@nn
Kjersti Flatmark
@sl
type
label
Kjersti Flatmark
@ast
Kjersti Flatmark
@da
Kjersti Flatmark
@de
Kjersti Flatmark
@en
Kjersti Flatmark
@es
Kjersti Flatmark
@fr
Kjersti Flatmark
@nb
Kjersti Flatmark
@nl
Kjersti Flatmark
@nn
Kjersti Flatmark
@sl
prefLabel
Kjersti Flatmark
@ast
Kjersti Flatmark
@da
Kjersti Flatmark
@de
Kjersti Flatmark
@en
Kjersti Flatmark
@es
Kjersti Flatmark
@fr
Kjersti Flatmark
@nb
Kjersti Flatmark
@nl
Kjersti Flatmark
@nn
Kjersti Flatmark
@sl
P1015
P101
P1015
P2038
Kjersti_Flatmark
P21
P214
70145970077632250860
P2287
P27
P31
P4012
P496
0000-0001-7409-0780
P569
1961-01-01T00:00:00Z
P6634
kjersti-flatmark-12031169
P735
P7859
viaf-70145970077632250860